FPC
ACRS icon

Falcon Point Capital’s Aclaris Therapeutics ACRS Stock Holding History

Falcon Point Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-18,965
Closed -$275K – 103
2018
Q3 		$275K Buy
18,965
+3,921
+26% +$67.2K 0.06% 87
2018
Q2 		$300K Buy
+15,044
New +$278K 0.06% 103
2018
Q1 		– Sell
-9,908
Closed -$244K – 117
2017
Q4 		$244K Sell
9,908
-7,883
-44% -$192K 0.04% 106
2017
Q3 		$449K Sell
17,791
-871
-5% -$23.3K 0.07% 98
2017
Q2 		$506K Buy
18,662
+5,116
+38% +$139K 0.07% 101
2017
Q1 		$404K Buy
13,546
+5,363
+66% +$155K 0.05% 102
2016
Q4 		$222K Buy
+8,183
New +$209K 0.03% 106

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Falcon Point Capital's ACRS Position: Q4 2018 in Review

Falcon Point Capital sold out of Aclaris Therapeutics (ACRS) in Q4 2018, closing a stake of 18,965 shares — an estimated $275K sold.

Falcon Point Capital first reported a position in ACRS in Q4 2016 and held it in 7 quarters. The position peaked at $506K in Q2 2017. 99 funds tracked by Wall St. Rank hold ACRS as of Q4 2018.

  • Falcon Point Capital reported no remaining Aclaris Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Falcon Point Capital sold 18,965 Aclaris Therapeutics shares in Q4 2018, an estimated $275K.
  • Falcon Point Capital first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 7 quarters.
  • Falcon Point Capital's Aclaris Therapeutics position peaked at $506K in Q2 2017.
  • 99 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2018.

Based on Falcon Point Capital's 13F filing for Q4 2018, filed 31 Jan 2019.